India · Delayed Price · Currency is INR SRF Limited Earnings Call Transcripts
Fiscal Year 2026
-
FY 2026 delivered strong growth with revenue up 7%, EBIT up 29%, and PAT up 47% year-over-year, driven by robust performance in chemicals and resilience amid global disruptions. Outlook for FY 2027 targets 15%-20% growth in chemicals, with major CapEx and new product launches planned.
-
Revenue grew 6% year-over-year with EBIT up 23% and net profit up 60%, led by strong chemicals performance and operational efficiencies. Specialty chemicals faced pricing pressure, but a robust pipeline and new investments in pharma and next-gen gases support a positive outlook.
-
Q2 FY26 saw 6% revenue and 56% EBIT growth, led by strong chemicals and refrigerants performance, with robust new product launches and a strategic Chemours partnership. CapEx for FY26 is set at INR 2,200–2,300 crore, and the company expects to surpass 20% full-year chemicals growth.
-
Q1 FY2026 saw robust revenue and profit growth, led by strong performance in chemicals, films, and foils, with new product launches and export gains offsetting domestic demand weakness. CapEx of INR 2,400–2,500 crore is planned, and guidance remains positive for FY2026.
Fiscal Year 2025
-
Q3 FY 2025 saw 14% YoY revenue growth, margin recovery, and strong chemicals and packaging films performance. Outlook for Q4 and FY 2026 is positive, with new product ramp-ups and robust CapEx plans. Export sales remain strong, but currency and pricing pressures persist.
-
Q2 FY25 saw 8% YoY revenue growth but weak chemical segment performance due to subdued agro demand and Chinese competition. Management expects a strong recovery in H2, with new product launches, major CapEx in advanced refrigerants and packaging, and improved order book supporting future growth.
-
Q1 FY2025 saw revenue of INR 3,464 crore and profit after tax of INR 252 crore, with chemicals facing headwinds but packaging films and technical textiles showing strong growth. Management remains confident in H2 recovery, maintaining 20% specialty chemical growth guidance and robust CapEx plans.